To our knowledge, this study is the first to investigate the impact of CYP2C8*3 (G416A; rs11572080) on imatinib therapy outcomes in Egyptian CML patients, highlighting the need for further validation through larger studies. The gene discussed is CYP2C8; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.